ASLAN Pharmaceuticals Limited – NASDAQ:ASLN

ASLAN Pharmaceuticals Limited stock price today

$0.56
-1.98
-78.04%
Financial Health
0
1
2
3
4
5
6
7
8
9

ASLAN Pharmaceuticals Limited stock price monthly change

+517.43%
month

ASLAN Pharmaceuticals Limited stock price quarterly change

+399.90%
quarter

ASLAN Pharmaceuticals Limited stock price yearly change

-37.96%
year

ASLAN Pharmaceuticals Limited key metrics

Market Cap
1.69M
Enterprise value
N/A
P/E
-0.79
EV/Sales
N/A
EV/EBITDA
0.37
Price/Sales
N/A
Price/Book
0.35
PEG ratio
N/A
EPS
-1.98
Revenue
N/A
EBITDA
-30.98M
Income
-35.02M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

ASLAN Pharmaceuticals Limited stock price history

ASLAN Pharmaceuticals Limited stock forecast

ASLAN Pharmaceuticals Limited financial statements

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN): Profit margin
Jul 2023 12M -1.88M -15.71%
Sep 2023 0 -9.70M
Dec 2023 0 -13.51M
Mar 2024 0 -9.91M
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN): Analyst Estimates
Dec 2023 0 -13.51M
Mar 2024 0 -9.91M
Sep 2025 0 -11.20M
Dec 2025 0 -11.76M
  • Analysts Price target

  • Financials & Ratios estimates

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN): Earnings per share (EPS)
2022-08-12 -1.50413 -0.95
2022-10-28 -0.67368 -0.8
2023-03-24 -1.21524 -1.04
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN): Debt to assets
Jul 2023 55205857 48.83M 88.46%
Sep 2023 44635264 45.51M 101.98%
Dec 2023 24626525 37.91M 153.95%
Mar 2024 20988241 38.95M 185.6%
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN): Cash Flow
Dec 2022 -6.23M -30.21K 9.11M
Mar 2023 0 0 0
Jul 2023 0 0 0
Sep 2023 0 0 0

ASLAN Pharmaceuticals Limited alternative data

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN): Employee count
Aug 2023 34
Sep 2023 34
Oct 2023 34
Nov 2023 34
Dec 2023 34
Jan 2024 34
Feb 2024 34
Mar 2024 34
Apr 2024 34
May 2024 35
Jun 2024 35
Jul 2024 35

ASLAN Pharmaceuticals Limited other data

6.02% -0.05%
of ASLN is owned by hedge funds
3.64M -28.55K
shares is hold by hedge funds
Wednesday, 17 July 2024
globenewswire.com
Monday, 15 July 2024
globenewswire.com
Tuesday, 4 June 2024
zacks.com
zacks.com
Tuesday, 21 May 2024
globenewswire.com
Thursday, 9 May 2024
globenewswire.com
Tuesday, 7 May 2024
globenewswire.com
Thursday, 2 May 2024
globenewswire.com
Tuesday, 30 April 2024
globenewswire.com
Monday, 22 April 2024
globenewswire.com
Friday, 19 April 2024
globenewswire.com
Friday, 12 April 2024
globenewswire.com
Tuesday, 9 April 2024
Zacks Investment Research
Wednesday, 27 March 2024
GlobeNewsWire
Tuesday, 12 March 2024
Zacks Investment Research
Tuesday, 2 January 2024
GlobeNewsWire
Thursday, 7 September 2023
GlobeNewsWire
Friday, 7 July 2023
Zacks Investment Research
Thursday, 6 July 2023
Market Watch
Wednesday, 5 July 2023
GlobeNewsWire
Thursday, 1 June 2023
GlobeNewsWire
Thursday, 27 April 2023
Zacks Investment Research
Wednesday, 5 April 2023
Zacks Investment Research
Thursday, 9 March 2023
Zacks Investment Research
Thursday, 2 March 2023
Zacks Investment Research
Friday, 16 December 2022
GlobeNewsWire
Friday, 2 September 2022
GlobeNewsWire
Wednesday, 6 April 2022
GlobeNewsWire
Friday, 21 January 2022
Zacks Investment Research
Benzinga
  • What's the price of ASLAN Pharmaceuticals Limited stock today?

    One share of ASLAN Pharmaceuticals Limited stock can currently be purchased for approximately $0.56.

  • When is ASLAN Pharmaceuticals Limited's next earnings date?

    Unfortunately, ASLAN Pharmaceuticals Limited's (ASLN) next earnings date is currently unknown.

  • Does ASLAN Pharmaceuticals Limited pay dividends?

    No, ASLAN Pharmaceuticals Limited does not pay dividends.

  • How much money does ASLAN Pharmaceuticals Limited make?

    ASLAN Pharmaceuticals Limited has a market capitalization of 1.69M. ASLAN Pharmaceuticals Limited made a loss 44.22M US dollars in net income (profit) last year or -$1.04 on an earnings per share basis.

  • What is ASLAN Pharmaceuticals Limited's stock symbol?

    ASLAN Pharmaceuticals Limited is traded on the NASDAQ under the ticker symbol "ASLN".

  • What is ASLAN Pharmaceuticals Limited's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of ASLAN Pharmaceuticals Limited?

    Shares of ASLAN Pharmaceuticals Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does ASLAN Pharmaceuticals Limited have?

    As Jul 2024, ASLAN Pharmaceuticals Limited employs 35 workers, which is 3% more then previous quarter.

  • When ASLAN Pharmaceuticals Limited went public?

    ASLAN Pharmaceuticals Limited is publicly traded company for more then 7 years since IPO on 4 May 2018.

  • What is ASLAN Pharmaceuticals Limited's official website?

    The official website for ASLAN Pharmaceuticals Limited is aslanpharma.com.

  • How can i contact ASLAN Pharmaceuticals Limited?

    ASLAN Pharmaceuticals Limited can be reached via phone at +65 6222 4235.

ASLAN Pharmaceuticals Limited company profile:

ASLAN Pharmaceuticals Limited

aslanpharma.com
Exchange:

NASDAQ

Full time employees:

35

Industry:

Biotechnology

Sector:

Healthcare

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

83 Clemenceau Avenue
Singapore, 239920

CIK: 0001722926
ISIN: US04522R2004
CUSIP: 04522R101